• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CalAmp Reports Fourth Quarter and Fiscal Year 2023 Financial Results

    4/27/23 4:05:42 PM ET
    $CAMP
    Get the next $CAMP alert in real time by email

    IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its fourth quarter and fiscal year 2023 ended February 28, 2023.

    "Fourth quarter results were highlighted by a significant increase in Adjusted EBITDA driven by a combination of gross margin increases and expense management," said Jeff Gardner, CalAmp's president and CEO. "The Company significantly reduced expenses through a restructuring late in Q4 to align the organization to a recurring revenue business model. As we enter this next fiscal year, our primary objective is to increase shareholder value by expanding the base of recurring application subscription customers by securing an increasing number of full stack solutions based new logos as well as up sell and cross sell new applications like Vision 2.0 to existing customers to fuel future recurring revenue growth, profitability and cash flow."

    Fourth Quarter Financial Overview

    • Total revenue in the quarter was $78.5 million, meeting expectations
    • Software and Subscription Services (S&SS) revenue grew 4% sequentially to a record $51.4 million. 78% of the eligible customers have been converted; transition is nearly complete
    • Telematics Products revenue in the quarter was $27.1 million, as customers transitioned to S&SS segments
    • Year End Remaining Performance Obligations (RPO) of $234 million
    • Telematics Products backlog was at $29 million, down sequentially by $8 million, reflecting improved supply
    • Restructured in January to reduce cash expenses by $10 to $12 million annually across COGS, OpX and CapX
    • Gross margin in the quarter increased 160 Bps to 35.3% quarter over quarter as net PPV declined
    • Adjusted EBITDA increased 44% to $6.8 million, or approximately 8.6% of revenue
    • GAAP net loss from continuing operations was $8.1 million, or a loss of $0.22 per share
    • Non-GAAP net income turned positive in Q4 with $1.5 million, or a gain of $0.06 per share
    • Ended the quarter with $42 million in cash and cash equivalents; have $34 million of undrawn line availability

    Business and Recent Highlights

    • Renewed recurring revenue agreement with Los Angeles Unified School District with 1,400 vehicles under contract
    • Secured recurring revenue agreement with Rockwood School District in the state of Missouri
    • New customer and partnership win with Noregon Systems, for predictive maintenance on heavy commercial trucks
    • Appointed tech finance veteran Jikun Kim as Chief Financial Officer

    Summary Financial Information From Continuing Operations:

    (In thousands except per share amounts)

      Three Months Ended  Fiscal Year Ended 
      February 28,  February 28, 
    Description 2023  2022  2023  2022 
    Revenues:            
    Software & Subscription Services (S&SS) $51,396  $41,236  $184,728  $154,315 
    Telematics Products  27,110   27,141   110,221   141,524 
      $78,506  $68,377  $294,949  $295,839 
    Gross profit  27,738   28,049   109,011   121,886 
                 
    Gross margin  35%  41%  37%  41%
                 
    Net loss $(8,090) $(9,181) $(32,490) $(31,148)
    Net loss per diluted share $(0.22) $(0.26) $(0.90) $(0.88)
    Non-GAAP measures:            
    Adjusted basis net income (loss) $1,515  $(305) $(2,759) $2,873 
    Adjusted basis net income (loss) per diluted share $0.06  $(0.01) $(0.08) $0.08 
    Adjusted EBITDA $6,754  $5,003  $18,074  $24,680 
    Adjusted EBITDA margin  9%  7%  6%  8%
                     



      February 28,  February 28, 
    Description 2023  2022 
    Cash and cash equivalents $41,928  $79,221 
    Working capital  68,295   90,928 
    Deferred revenue  36,552   39,670 
    Total debt (carrying value)  228,121   192,288 
           



      February 28,  February 28, 
    S&SS Supplemental Information: 2023  2022 
    Remaining performance obligations $234,494  $200,103 
    Subscribers  1,595   1,060 
             

    First Quarter Fiscal Year 2024 Business Outlook

    We expect FY24 Q1 revenues to range between $72 and $78 million with adjusted EBITDA between $5 and $9 million.

    A reconciliation of non-GAAP guidance financial measures to corresponding GAAP guidance financial measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty and potential variability of expenses, such as stock-based compensation expense-related charges, that may be incurred in the future and cannot be reasonably determined or predicted at this time. It is important to note that these factors could be material to our results of operations computed in accordance with GAAP.

    Conference Call and Webcast

    CalAmp is hosting a conference call for analysts and investors to discuss its fourth quarter fiscal year 2023 results at 2:00 p.m. Pacific Time today. Participants can listen in via webcast by visiting the Investor Relations section of its website at www.calamp.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A replay of the webcast will be available for 90 days after the call. The conference call can also be accessed by dialing 833-470-1428 (+1-404-975-4839 for international callers)and using the Conference ID #859160. Following the call, an audio replay will also be available by calling 866-813-9403 or +44-204-525-0658 and entering the Conference ID #390203. The audio replay will be available through May 4, 2023.

    About CalAmp

    CalAmp (NASDAQ:CAMP) provides flexible solutions to help organizations worldwide monitor, track and protect their vital assets. Our unique combination of software, devices, and platform enables over 14,000 commercial and government organizations worldwide to increase efficiency, safety and transparency while accommodating the unique ways they do business. With over 10 million active edge devices and 275+ issued or pending patents, CalAmp is the telematics leader organizations turn to for innovation and dependability. For more information, visit calamp.com, or LinkedIn, Twitter, YouTube or CalAmp Blog.

    Forward-Looking Statements

    This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning CalAmp. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, (ii) our competitive position and opportunities, and (iii) other statements identified by words such as such as "may", "will", "expect", "intend", "plan", "potential", "believe", "seek", "could", "estimate", "judgment", "targeting", "should", "anticipate", "predict", "project", "aim", "goal", and similar words, phrases or expressions. These forward-looking statements are based on management's current expectations and beliefs, as well as assumptions made by, and information currently available to, management, current market trends and market conditions, and involve risks and uncertainties, many of which are outside of our control, and which may cause actual results to differ materially from those contained in forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect future results include any risks associated with global economic conditions and concerns; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the recent coronavirus (COVID-19) pandemic; global component shortages due to supply chain constraints caused by the COVID-19 pandemic; disruptions in sales, operations, relationships with customers, suppliers, employees; our ability to successfully and timely accomplish our transformation to a SaaS solutions provider; our transition out of the automotive vehicle financing business; competitive pressures; pricing declines; demand for our telematics products; rates of growth in our target markets; prolonged disruptions of our contract manufacturers' facilities or other significant operations; force majeure or force-majeure-like events at our contract manufacturers' facilities including component shortages; the ongoing diversification of our global supply chain; our dependence on outsourced service providers for certain key business services and their ability to execute to our requirements; our ability to improve gross margin; cost-containment measures; legislative, trade, tariff, and regulatory actions; integration, unexpected charges or expenses in connection with acquisitions; the impact of legal proceedings and compliance risks; the impact on our business and reputation from information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; the ability of the Company to comply with laws and regulations regarding data protection; our ability to protect our intellectual property and the unpredictability of any associated litigation expenses; any expenses or reputational damage associated with resolving customer product and warranty and indemnification claims; our ability to sell to new types of customers and to keep pace with technological advances; market acceptance of the end products into which our products are designed; and other events and trends on a national, regional and global scale, including those of a political, economic, business, competitive, and regulatory nature. More information on these risks and other potential factors that could affect our financial results is included in our filings with the U.S. Securities and Exchange Commission ("SEC"), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings, which you may obtain for free at the SEC's website at http://www.sec.gov. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise, which speak as of their respective dates except as required by law.

    Non-GAAP Financial Measures

    "GAAP" refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This announcement includes non-GAAP financial measures, as defined in Regulation G promulgated by the SEC. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. These non-GAAP financial measures are provided in addition to, and not as a substitute for measures of financial performance prepared in accordance with GAAP.

    In this announcement, we report the non-GAAP financial measures of Adjusted basis net income (loss), Adjusted basis net income (loss) per diluted share, Adjusted EBITDA (earnings before investment income, interest expense, taxes, depreciation, amortization, stock-based compensation, acquisition and integration expenses, non-cash costs and expenses arising from purchase accounting adjustments, litigation and legal expenses, impairment losses and certain other adjustments as detailed in the accompanying non-GAAP reconciliation), and Adjusted EBITDA margin. Adjusted basis net income (loss) excludes the impact of intangible asset amortization expense, stock-based compensation, non-cash interest expense, acquisition and integration expenses, non-cash costs and expenses arising from purchase accounting adjustments, litigation and legal expenses, income tax provision adjustments, impairment losses and certain other adjustments as shown in the non-GAAP reconciliation provided in the table at the end of this announcement. We use these non-GAAP financial measures to provide investors with additional information about our financial performance and future prospects of our core business activities. Internally, these non-GAAP measures are significant measures used by management for purposes of evaluating our core operating performance, establishing internal budgets, calculating return on investment for development programs and growth initiatives, comparing performance with internal forecasts and targeted business models, strategic planning, evaluating and valuing potential acquisition candidates and how their operations compare to our operations, and benchmarking performance externally against our competitors. We believe this non-GAAP financial information provides additional insight into our ongoing performance and have therefore chosen to provide this information to investors to help them evaluate our results of ongoing operations and enable additional period-to-period comparisons. The presentation of these and other similar items in our non-GAAP financial results should not be interpreted as implying that these items are non-recurring, infrequent, or unusual.

    CalAmp, LoJack, TRACKER, Here Comes The Bus, Bus Guardian, iOn Vision, CrashBoxx and associated logos are among the trademarks of CalAmp and/or its affiliates in the United States, certain other countries and/or the EU. Spireon acquired the LoJack® U.S. Stolen Vehicle Recovery (SVR) business from CalAmp and holds an exclusive license to the LoJack mark in the United States and Canada. Any other trademarks or trade names mentioned are the property of their respective owners.

    AT CALAMP:

    Jikun Kim

    SVP & CFO

    [email protected]
            AT SHELTON GROUP:

    Leanne K. Sievers

    (949) 224.3874

    [email protected]
       

    CALAMP CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands, except per share amounts)

    (Unaudited)

     Three Months Ended  Fiscal Year Ended 
     February 28,  February 28, 
      2023   2022   2023   2022 
                    
    Revenues$78,506  $68,377  $294,949  $295,839 
    Cost of revenues 50,768  $40,328   185,938   173,953 
    Gross profit 27,738   28,049   109,011   121,886 
    Operating expenses:               
    Research and development 5,334  $6,596   24,570   28,444 
    Selling and marketing 10,691  $10,816   47,389   48,564 
    General and administrative 11,955  $13,674   51,819   52,333 
    Intangible asset amortization 1,337  $1,382   5,332   5,415 
    Restructuring 4,586  $264   4,586   600 
      33,903   32,732   133,696   135,356 
    Operating loss (6,165)  (4,683)  (24,685)  (13,470)
    Non-operating income (expense):               
    Investment income 343  $(43)  989   1,175 
    Interest expense (1,615) $(3,840)  (6,260)  (15,323)
    Other expense, net (145) $(359)  (1,383)  (2,443)
      (1,417)  (4,242)  (6,654)  (16,591)
    Loss from continuing operations before income taxes (7,582)  (8,925)  (31,339)  (30,061)
    Income tax provision from continuing operations (508) $(256)  (1,151)  (1,087)
    Net loss from continuing operations (8,090)  (9,181)  (32,490)  (31,148)
    Net income from discontinued operations, net of tax -  $-   -   3,157 
    Net loss$(8,090) $(9,181) $(32,490) $(27,991)
    Loss per share - continuing operations:               
    Basic$(0.22) $(0.26) $(0.90) $(0.88)
    Diluted$(0.22) $(0.26) $(0.90) $(0.88)
    Earnings per share - discontinued operations:               
    Basic$-  $-  $-  $0.09 
    Diluted$-  $-  $-  $0.09 
    Shares used in computing earnings (loss) per share:               
    Basic 36,132   35,552   36,132   35,254 
    Diluted 36,132   35,552   36,132   35,254 
                    

    CALAMP CORP.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)

     February 28,  February 28, 
     2023  2022 
    Assets      
            
    Current assets:       
    Cash and cash equivalents$41,928  $79,221 
    Accounts receivable, net 82,946   61,544 
    Inventories 23,902   18,269 
    Prepaid expenses and other current assets 26,019   22,348 
    Total current assets 174,795   181,382 
            
    Property and equipment, net 32,832   37,674 
    Operating lease right-of-use assets 12,293   12,327 
    Deferred income tax assets 3,275   4,165 
    Goodwill 94,214   94,436 
    Other intangible assets, net 26,633   31,965 
    Other assets 36,078   29,632 
    Total assets$380,120  $391,581 
            
    Liabilities and Stockholders' Equity       
            
    Current liabilities:       
    Current portion of long-term debt$705  $2,585 
    Accounts payable 52,716   31,815 
    Accrued payroll and employee benefits 11,766   10,929 
    Deferred revenue 25,448   26,174 
    Other current liabilities 15,865   18,951 
    Total current liabilities 106,500   90,454 
            
    Long-term debt, net of current portion 227,416   189,703 
    Operating lease liabilities 12,314   13,382 
    Other non-current liabilities 19,583   22,640 
    Total liabilities 365,813   316,179 
    Stockholders' equity:       
    Common stock 374   361 
    Additional paid-in capital 184,672   242,386 
    Accumulated deficit (168,816)  (165,965)
    Accumulated other comprehensive loss (1,923)  (1,380)
    Total stockholders' equity 14,307   75,402 
    Total liabilities and stockholders' equity$380,120  $391,581 
            

    CALAMP CORP.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

    (Unaudited)

     Fiscal Year Ended 
     February 28, 
      2023   2022 
    CASH FLOWS FROM OPERATING ACTIVITIES:       
    Net loss$(32,490) $(27,991)
    Less: net income from discontinued operations, net of tax -   3,157 
    Net loss from continuing operations (32,490)  (31,148)
            
    Depreciation expense 16,426   17,389 
    Intangible asset amortization 5,332   5,415 
    Stock-based compensation 10,211   11,321 
    Amortization of debt issuance costs and discount 1,151   10,411 
    Non-cash operating lease cost 3,433   3,713 
    Revenue assigned to factors (2,680)  (4,566)
    Deferred tax assets, net 676   465 
    Other 74   595 
    Changes in operating assets and liabilities of continuing operations (25,065)  (17,418)
    Net cash used in operating activities - continuing operations (22,932)  (3,823)
    Net cash used in operating activities - discontinued operations -   (395)
    NET CASH USED IN OPERATING ACTIVITIES (22,932)  (4,218)
            
    CASH FLOWS FROM INVESTING ACTIVITIES:       
    Capital expenditures (11,100)  (13,298)
    Net cash used in investing activities - continuing operations (11,100)  (13,298)
    Net cash provided by investing activities - discontinued operations -   5,721 
    NET CASH USED IN INVESTING ACTIVITIES (11,100)  (7,577)
            
    CASH FLOWS FROM FINANCING ACTIVITIES:       
    Taxes paid related to net share settlement of vested equity awards (1,865)  (4,173)
    Proceeds from exercise of stock options and contributions to employee stock purchase plan 956   1,530 
    NET CASH USED IN FINANCING ACTIVITIES (909)  (2,643)
            
    EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (2,352)  (965)
    Net change in cash and cash equivalents (37,293)  (15,403)
    Cash and cash equivalents at beginning of year 79,221   94,624 
    Cash and cash equivalents at end of year$41,928  $79,221 
            

    CALAMP CORP.

    RECONCILIATION OF NON-GAAP MEASURES TO GAAP

    (Unaudited)

    GAAP refers to financial information presented in accordance with U.S. Generally Accepted Accounting Principles. This announcement includes non-GAAP financial measures, as defined in Regulation G promulgated by the Securities and Exchange Commission. We believe that our presentation of non-GAAP financial measures provides useful supplementary information to investors. The presentation of non-GAAP financial measures is not meant to be considered in isolation from or as a substitute for results prepared in accordance with GAAP.

    In this announcement, we report the non-GAAP financial measures of Adjusted basis net income (loss), Adjusted basis net income (loss) per diluted share, Adjusted EBITDA (earnings before investment income, interest expense, taxes, depreciation, amortization, stock-based compensation and other adjustments as identified below), and Adjusted EBITDA margin. We use these non-GAAP financial measures to provide investors with an overall understanding of the financial performance and future prospects of our core business activities. Specifically, we believe that the use of these non-GAAP measures facilitates the comparison of results of core business operations between current and past periods.

    The reconciliation of GAAP basis net loss to Adjusted basis (non-GAAP) net income (loss) is as follows (in thousands except per share amounts):

     Three Months Ended  Fiscal Year Ended 
     February 28,  February 28, 
     2023  2022  2023  2022 
                    
    GAAP basis net loss$(8,090) $(9,181) $(32,490) $(27,991)
                    
    Net income from discontinued operations, net of tax -   -   -   (3,157)
    Intangible asset amortization 1,337   1,382   5,332   5,415 
    Stock-based compensation 2,025   2,760   10,211   11,321 
    Non-cash interest expense 274   2,600   1,151   10,411 
    GAAP basis income tax provision 508   256   1,151   1,087 
    Litigation and non-recurring legal expenses 524   1,186   5,158   2,518 
    Restructuring 4,586   264   4,586   600 
    Costs incurred in transition of LoJack North America business to acquiror (b) 130   319   1,347   2,103 
    Other 251   114   1,325   1,161 
    Adjusted basis income (loss) before income taxes 1,545   (300)  (2,229)  3,468 
    Income tax provision (non-GAAP basis) (a) (30)  (5)  (530)  (595)
    Adjusted basis net income (loss)$1,515  $(305) $(2,759) $2,873 
                    
    Adjusted basis net income (loss) per diluted share$0.06  $(0.01) $(0.08) $0.08 
                    
    Weighted average common shares outstanding on a diluted basis 44,509   35,552   36,132   36,088 
                    

    The reconciliation of GAAP-basis net loss to Adjusted EBITDA and the calculation of Adjusted EBITDA margin are as follows (dollars in thousands):

     Three Months Ended  Fiscal Year Ended 
     February 28,  February 28, 
     2023  2022  2023  2022 
                    
    GAAP basis net loss$(8,090) $(9,181) $(32,490) $(27,991)
                    
    Net income from discontinued operations, net of tax -   -   -   (3,157)
    Investment (income) loss (343)  43   (989)  (1,175)
    Interest expense 1,615   3,840   6,260   15,323 
    Income tax provision 508   256   1,151   1,087 
    Depreciation and amortization 5,655   5,718   21,758   22,804 
    Stock-based compensation 2,025   2,760   10,211   11,321 
    Litigation and non-recurring legal expenses 524   1,186   5,158   2,518 
    Restructuring 4,586   264   4,586   600 
    Costs incurred in transition of LoJack North America business to acquiror (b) 130   319   1,347   2,103 
    Other 144   (202)  1,082   1,247 
    Adjusted EBITDA$6,754  $5,003  $18,074  $24,680 
                    
    Revenues$78,506  $68,377  $294,949  $295,839 
                    
    Adjusted EBITDA margin 9%  7%  6%  8%
                    

    (a) The non-GAAP income tax provision represents cash taxes paid or payable for the period after giving effect to the utilization of net operating losses and tax credit carryforwards.

    (b) Costs incurred in transition of business to acquiror are attributable to the wind-down and transfer of the LoJack North America business to Spireon.



    Primary Logo

    Get the next $CAMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAMP

    DatePrice TargetRatingAnalyst
    11/5/2024Outperform
    William Blair
    11/5/2024$18.00Overweight
    Piper Sandler
    11/5/2024$23.00Overweight
    JP Morgan
    8/16/2022$8.00 → $10.00Hold → Buy
    Craig Hallum
    12/22/2021$15.00 → $14.00Buy
    Canaccord Genuity
    12/22/2021$14.00 → $10.00Buy → Hold
    Craig-Hallum
    9/24/2021$16.00 → $14.00Buy
    Craig Hallum
    6/25/2021$19.00 → $18.50Buy
    Roth Capital
    More analyst ratings

    $CAMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes CMP-SYNGAP-01 administration led to a significant increase in SYNGAP1 protein levels in relevant brain regions in non-human primates (NHPs) Patient safety and pharmacokinetic data from single ascending dose (SAD) cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers highlighted CAMBRIDGE, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th

      5/16/25 6:00:00 AM ET
      $CAMP
    • CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

      Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations to highlight meaningful increase in SYNGAP1 protein, driven by lead ASO candidate, CMP-SYNGAP-01, in non-human primates (NHP) and review interim SAD data from the Phase 1 trial of CMP-CPS-0

      5/13/25 4:05:11 PM ET
      $CAMP
    • CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

      Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced three

      4/28/25 4:30:00 PM ET
      $CAMP

    $CAMP
    Leadership Updates

    Live Leadership Updates

    See more
    • CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

      With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4's multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced the appointments of Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, to the Company's Board of Directors. "We are delighted to welcome Drs. William

      3/18/25 8:00:00 AM ET
      $CAMP
    • CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

      CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

      12/10/24 8:00:00 AM ET
      $CAMP
      $KRRO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CalAmp Appoints Chris Adams as President and Chief Executive Officer

      IRVINE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, is pleased to announce that Chris Adams will be joining the company as President and Chief Executive Officer (CEO), effective January 22, 2024. Adams is an accomplished technology leader who brings a wealth of knowledge and experience to CalAmp. He possesses a unique combination of technical depth, operational skills, and general management experience from a broad range of technology companies – most recently as VP/GM of the Automotive Sensing Division at onsemi. "After a comprehensiv

      1/8/24 6:30:00 AM ET
      $CAMP

    $CAMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Bumcrot David

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:09:40 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Medical Officer Maricich Yuri

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:08:11 PM ET
      $CAMP
    • SEC Form 4 filed by Chief Financial Officer Gold Kelly

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      4/3/25 4:07:07 PM ET
      $CAMP

    $CAMP
    SEC Filings

    See more
    • CAMP4 Therapeutics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/16/25 6:28:22 AM ET
      $CAMP
    • SEC Form SCHEDULE 13G filed by CAMP4 Therapeutics Corporation

      SCHEDULE 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      5/14/25 1:45:31 PM ET
      $CAMP
    • SEC Form 10-Q filed by CAMP4 Therapeutics Corporation

      10-Q - Camp4 Therapeutics Corp (0001736730) (Filer)

      5/13/25 4:26:54 PM ET
      $CAMP

    $CAMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on CAMP4 Therapeutics

      William Blair initiated coverage of CAMP4 Therapeutics with a rating of Outperform

      11/5/24 7:23:37 AM ET
      $CAMP
    • Piper Sandler initiated coverage on CAMP4 Therapeutics with a new price target

      Piper Sandler initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $18.00

      11/5/24 6:14:46 AM ET
      $CAMP
    • JP Morgan initiated coverage on CAMP4 Therapeutics with a new price target

      JP Morgan initiated coverage of CAMP4 Therapeutics with a rating of Overweight and set a new price target of $23.00

      11/5/24 6:14:20 AM ET
      $CAMP

    $CAMP
    Financials

    Live finance-specific insights

    See more
    • CalAmp Reports Third Quarter Fiscal Year 2024 Financial Results

      IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company that helps organizations monitor, track and protect their vital assets, today reported financial results for its third quarter of fiscal year 2024 ended November 30, 2023. Third Quarter Fiscal Year 2024 Financial Overview    Revenue was $53.6 million, representing a 13% decline QoQ and a 32% decline YoY driven primarily by softer demand in the TSP market segment.Gross margin was 33%, representing a decline of approximately 340 bps QoQ and 100 bps decline YoY as a result of a shift in product mix and a higher-than-normal reserve for excess and obsolete inventory.S&SS revenue was $34.5

      1/9/24 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Date for Fiscal 2024 Third Quarter Earnings Conference Call

      IRVINE, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a leading telematics solution provider that helps organizations improve operational performance, today announced that it will release its fiscal 2024 third quarter financial results after market close on Tuesday, January 9, 2024. In addition, the Company will host a conference call at 5:00 p.m. Eastern (2:00 p.m. Pacific) on January 9, 2024, to discuss its financial results. The call may be accessed via webcast by visiting the Investor Relations section of CalAmp's website at CalAmp IR Web Site. Please go to the website at least 15 minutes early to register, download and install any necessary audio software. A repla

      12/26/23 4:30:00 PM ET
      $CAMP
    • CalAmp Announces Completion of Strategic Financing with Lynrock Lake

      IRVINE, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CalAmp (NASDAQ:CAMP), a connected intelligence company helping people and organizations improve operational performance with telematics solutions, today announced the closing of a $45 million strategic financing with Lynrock Lake Master Fund LP ("Lynrock") in the form of a term loan maturing in November 2027. Lynrock is an existing holder of a large majority of CalAmp's 2.00% Convertible Senior Notes maturing in August 2025 (the "Notes"). In connection with the execution of the term loan agreement, CalAmp is amending the Notes to add a security interest. "As a long-standing investor in CalAmp, we are pleased to provide the company with add

      12/18/23 4:31:00 PM ET
      $CAMP

    $CAMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 6:49:57 PM ET
      $CAMP
    • SEC Form SC 13D filed by CAMP4 Therapeutics Corporation

      SC 13D - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 5:50:56 PM ET
      $CAMP
    • SEC Form SC 13G filed by CAMP4 Therapeutics Corporation

      SC 13G - Camp4 Therapeutics Corp (0001736730) (Subject)

      10/22/24 4:19:08 PM ET
      $CAMP

    $CAMP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Large owner Polaris Management Co. Vii, L.L.C. converted options into 1,715,972 shares and bought $9,999,990 worth of shares (909,090 units at $11.00) (SEC Form 4)

      4/A - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/22/24 5:31:39 PM ET
      $CAMP
    • Large owner Northpond Ventures Ii Gp, Llc converted options into 1,474,608 shares and bought $8,399,996 worth of shares (763,636 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 6:34:47 PM ET
      $CAMP
    • Large owner Ah Equity Partners Bio I, L.L.C. converted options into 1,398,067 shares and bought $7,999,992 worth of shares (727,272 units at $11.00) (SEC Form 4)

      4 - Camp4 Therapeutics Corp (0001736730) (Issuer)

      10/17/24 5:05:20 PM ET
      $CAMP